 Todd Bull
Concepts (334)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 45 | 2024 | 1910 | 3.910 |
Why?
| | Scleroderma, Systemic | 6 | 2019 | 122 | 1.680 |
Why?
| | Pulmonary Embolism | 5 | 2022 | 226 | 1.250 |
Why?
| | Ventricular Dysfunction, Right | 7 | 2023 | 238 | 1.230 |
Why?
| | Vena Cava Filters | 2 | 2020 | 61 | 0.800 |
Why?
| | Thrombolytic Therapy | 3 | 2021 | 142 | 0.750 |
Why?
| | Epoprostenol | 5 | 2024 | 136 | 0.750 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 80 | 0.680 |
Why?
| | Airway Obstruction | 1 | 2021 | 162 | 0.650 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 494 | 0.640 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2024 | 1040 | 0.620 |
Why?
| | Familial Primary Pulmonary Hypertension | 12 | 2023 | 198 | 0.600 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 270 | 0.600 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 767 | 0.570 |
Why?
| | Thrombosis | 4 | 2023 | 371 | 0.560 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2020 | 301 | 0.550 |
Why?
| | Growth Differentiation Factor 15 | 3 | 2013 | 40 | 0.520 |
Why?
| | Vascular Resistance | 5 | 2021 | 375 | 0.510 |
Why?
| | Herpesviridae Infections | 3 | 2008 | 147 | 0.500 |
Why?
| | Exercise Test | 4 | 2024 | 625 | 0.500 |
Why?
| | Endovascular Procedures | 1 | 2020 | 312 | 0.500 |
Why?
| | Hypoxia | 6 | 2024 | 1112 | 0.490 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 131 | 0.480 |
Why?
| | Altitude Sickness | 1 | 2017 | 153 | 0.470 |
Why?
| | Pulmonary Artery | 10 | 2023 | 1086 | 0.450 |
Why?
| | Vasodilator Agents | 4 | 2023 | 331 | 0.430 |
Why?
| | Echocardiography | 2 | 2020 | 642 | 0.430 |
Why?
| | Ventricular Function, Right | 5 | 2024 | 285 | 0.420 |
Why?
| | Humans | 69 | 2024 | 137585 | 0.410 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 938 | 0.410 |
Why?
| | Perioperative Care | 1 | 2014 | 178 | 0.380 |
Why?
| | Altitude | 1 | 2017 | 488 | 0.380 |
Why?
| | Anticoagulants | 5 | 2023 | 664 | 0.380 |
Why?
| | Endothelial Cells | 5 | 2011 | 785 | 0.380 |
Why?
| | Sulfones | 1 | 2012 | 110 | 0.360 |
Why?
| | Oxygen Consumption | 2 | 2024 | 696 | 0.350 |
Why?
| | Blood Cells | 1 | 2010 | 40 | 0.340 |
Why?
| | Herpesvirus 8, Human | 3 | 2008 | 65 | 0.330 |
Why?
| | Hypertension, Portal | 2 | 2020 | 64 | 0.320 |
Why?
| | Venous Thromboembolism | 3 | 2021 | 316 | 0.320 |
Why?
| | Piperazines | 1 | 2012 | 350 | 0.320 |
Why?
| | Blood Coagulation | 3 | 2021 | 255 | 0.310 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 301 | 0.310 |
Why?
| | End Stage Liver Disease | 2 | 2020 | 82 | 0.310 |
Why?
| | Virus Diseases | 1 | 2011 | 212 | 0.300 |
Why?
| | Lung | 8 | 2022 | 4060 | 0.270 |
Why?
| | Walk Test | 2 | 2024 | 76 | 0.270 |
Why?
| | Acute Lung Injury | 1 | 2010 | 287 | 0.270 |
Why?
| | Time Factors | 2 | 2017 | 6828 | 0.260 |
Why?
| | Blood Vessels | 1 | 2008 | 187 | 0.260 |
Why?
| | Middle Aged | 20 | 2024 | 33479 | 0.250 |
Why?
| | Heart Ventricles | 5 | 2024 | 788 | 0.250 |
Why?
| | Male | 28 | 2024 | 67762 | 0.240 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2005 | 10 | 0.240 |
Why?
| | Microarray Analysis | 1 | 2005 | 117 | 0.240 |
Why?
| | Respiratory Function Tests | 1 | 2007 | 600 | 0.240 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2007 | 446 | 0.230 |
Why?
| | Cardiac Catheterization | 5 | 2023 | 530 | 0.230 |
Why?
| | Aromatase Inhibitors | 1 | 2024 | 54 | 0.220 |
Why?
| | Female | 27 | 2024 | 73304 | 0.220 |
Why?
| | Pulmonary Emphysema | 2 | 2007 | 288 | 0.220 |
Why?
| | Castleman Disease | 1 | 2003 | 13 | 0.210 |
Why?
| | Exercise | 4 | 2024 | 2057 | 0.190 |
Why?
| | Gene Expression Profiling | 2 | 2007 | 1774 | 0.190 |
Why?
| | Heparin | 2 | 2021 | 261 | 0.190 |
Why?
| | Vascular Neoplasms | 1 | 2022 | 18 | 0.190 |
Why?
| | Biopsy | 1 | 2005 | 1129 | 0.190 |
Why?
| | Cross-Over Studies | 1 | 2024 | 564 | 0.180 |
Why?
| | Endothelium, Vascular | 6 | 2007 | 927 | 0.180 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 24 | 0.180 |
Why?
| | Embolectomy | 1 | 2020 | 13 | 0.170 |
Why?
| | Growth Differentiation Factor 2 | 1 | 2020 | 2 | 0.170 |
Why?
| | Aromatase | 1 | 2020 | 32 | 0.170 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2020 | 25 | 0.170 |
Why?
| | Pulmonary Circulation | 4 | 2023 | 429 | 0.170 |
Why?
| | Forced Expiratory Volume | 1 | 2021 | 531 | 0.170 |
Why?
| | Thrombectomy | 1 | 2020 | 69 | 0.160 |
Why?
| | Tuberculosis | 1 | 2003 | 279 | 0.160 |
Why?
| | Drug Resistance | 1 | 2020 | 169 | 0.160 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 224 | 0.160 |
Why?
| | Aged | 12 | 2024 | 23961 | 0.160 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2020 | 135 | 0.160 |
Why?
| | Risk Factors | 7 | 2018 | 10388 | 0.150 |
Why?
| | Sildenafil Citrate | 2 | 2023 | 58 | 0.150 |
Why?
| | Vascular Stiffness | 1 | 2023 | 494 | 0.150 |
Why?
| | Polymerase Chain Reaction | 3 | 2008 | 1062 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 318 | 0.140 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2018 | 69 | 0.140 |
Why?
| | Critical Illness | 2 | 2021 | 811 | 0.140 |
Why?
| | Estrogens | 1 | 2020 | 367 | 0.140 |
Why?
| | Acute Disease | 1 | 2020 | 1007 | 0.140 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 27 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.140 |
Why?
| | Schistosoma | 1 | 2017 | 28 | 0.140 |
Why?
| | Hemodynamics | 2 | 2014 | 1113 | 0.140 |
Why?
| | Purines | 2 | 2023 | 176 | 0.130 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2021 | 99 | 0.130 |
Why?
| | Transforming Growth Factor beta | 2 | 2017 | 480 | 0.130 |
Why?
| | Risk Assessment | 3 | 2023 | 3457 | 0.130 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2016 | 37 | 0.130 |
Why?
| | Adult | 15 | 2024 | 37929 | 0.120 |
Why?
| | Bone Marrow Cells | 1 | 2017 | 316 | 0.120 |
Why?
| | Pandemics | 2 | 2021 | 1639 | 0.120 |
Why?
| | Systole | 1 | 2016 | 189 | 0.120 |
Why?
| | Treatment Outcome | 8 | 2024 | 10811 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
| | Patient Care Team | 1 | 2020 | 631 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2013 | 1050 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.120 |
Why?
| | Cohort Studies | 3 | 2017 | 5742 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2023 | 15657 | 0.110 |
Why?
| | Health Surveys | 1 | 2017 | 514 | 0.110 |
Why?
| | Intensive Care Units | 1 | 2020 | 827 | 0.110 |
Why?
| | Myocardial Contraction | 1 | 2016 | 341 | 0.110 |
Why?
| | Prognosis | 3 | 2013 | 4030 | 0.110 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2011 | 82 | 0.110 |
Why?
| | ROC Curve | 1 | 2016 | 554 | 0.110 |
Why?
| | Positive-Pressure Respiration | 1 | 2014 | 80 | 0.110 |
Why?
| | Heart Failure | 2 | 2020 | 2236 | 0.110 |
Why?
| | Blood Pressure | 2 | 2016 | 1786 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 552 | 0.110 |
Why?
| | Anesthetics | 1 | 2014 | 81 | 0.100 |
Why?
| | Lung Diseases, Interstitial | 2 | 2013 | 638 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 429 | 0.100 |
Why?
| | Respiratory System Agents | 1 | 2013 | 22 | 0.100 |
Why?
| | Drug Discovery | 1 | 2013 | 142 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 558 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5131 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1587 | 0.100 |
Why?
| | Drug Storage | 1 | 2012 | 57 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 24 | 0.090 |
Why?
| | Drug Stability | 1 | 2012 | 167 | 0.090 |
Why?
| | Drug Approval | 1 | 2012 | 88 | 0.090 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2011 | 10 | 0.090 |
Why?
| | Phenotype | 3 | 2010 | 3196 | 0.090 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2011 | 34 | 0.090 |
Why?
| | Troponin | 1 | 2011 | 50 | 0.090 |
Why?
| | Blood Gas Analysis | 1 | 2011 | 74 | 0.090 |
Why?
| | Europe | 1 | 2012 | 414 | 0.090 |
Why?
| | Reproducibility of Results | 2 | 2010 | 3284 | 0.090 |
Why?
| | Hyponatremia | 1 | 2011 | 42 | 0.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 77 | 0.090 |
Why?
| | Medical History Taking | 1 | 2011 | 117 | 0.090 |
Why?
| | Antithrombins | 1 | 2011 | 60 | 0.090 |
Why?
| | Case-Control Studies | 4 | 2020 | 3556 | 0.090 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 28 | 0.090 |
Why?
| | Ultrasonography | 2 | 2011 | 759 | 0.090 |
Why?
| | Double-Blind Method | 3 | 2024 | 1993 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3566 | 0.080 |
Why?
| | Registries | 3 | 2022 | 2035 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 2031 | 0.080 |
Why?
| | Mutation, Missense | 1 | 2011 | 341 | 0.080 |
Why?
| | Demography | 1 | 2010 | 291 | 0.080 |
Why?
| | Aldosterone | 1 | 2009 | 45 | 0.080 |
Why?
| | Cluster Analysis | 1 | 2010 | 499 | 0.080 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 365 | 0.080 |
Why?
| | Vasopressins | 1 | 2009 | 64 | 0.070 |
Why?
| | Caspase 7 | 1 | 2008 | 22 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2526 | 0.070 |
Why?
| | In Situ Nick-End Labeling | 1 | 2008 | 124 | 0.070 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 139 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 976 | 0.070 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2008 | 43 | 0.070 |
Why?
| | Prospective Studies | 4 | 2022 | 7604 | 0.070 |
Why?
| | Electrocardiography | 1 | 2011 | 629 | 0.070 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 110 | 0.070 |
Why?
| | Intramolecular Oxidoreductases | 2 | 2005 | 68 | 0.070 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2005 | 155 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 390 | 0.070 |
Why?
| | Caspase 3 | 1 | 2008 | 246 | 0.070 |
Why?
| | Animals | 10 | 2017 | 36940 | 0.070 |
Why?
| | United States | 4 | 2022 | 14841 | 0.070 |
Why?
| | Research Design | 1 | 2013 | 1139 | 0.070 |
Why?
| | Acrolein | 1 | 2007 | 23 | 0.070 |
Why?
| | Survival Analysis | 1 | 2010 | 1325 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2010 | 1178 | 0.060 |
Why?
| | Colorado | 1 | 2017 | 4565 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1509 | 0.060 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2007 | 145 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 852 | 0.060 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2005 | 26 | 0.060 |
Why?
| | Quality of Life | 3 | 2022 | 2892 | 0.060 |
Why?
| | Pleural Diseases | 1 | 2005 | 23 | 0.060 |
Why?
| | Endothelial Growth Factors | 2 | 2002 | 64 | 0.060 |
Why?
| | Comorbidity | 1 | 2010 | 1622 | 0.060 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2005 | 89 | 0.060 |
Why?
| | Lymphokines | 2 | 2002 | 131 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 4193 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 1091 | 0.050 |
Why?
| | Cattle | 2 | 2017 | 984 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2008 | 771 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2008 | 778 | 0.050 |
Why?
| | Apoptosis | 3 | 2008 | 2553 | 0.050 |
Why?
| | Blood Circulation | 1 | 2003 | 41 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 172 | 0.050 |
Why?
| | CD36 Antigens | 1 | 2003 | 36 | 0.050 |
Why?
| | Algorithms | 1 | 2011 | 1704 | 0.050 |
Why?
| | Vasodilation | 3 | 2010 | 499 | 0.050 |
Why?
| | E-Selectin | 1 | 2003 | 57 | 0.050 |
Why?
| | Forecasting | 1 | 2005 | 389 | 0.050 |
Why?
| | Veins | 1 | 2003 | 63 | 0.050 |
Why?
| | Blood | 1 | 2003 | 107 | 0.050 |
Why?
| | Adolescent | 4 | 2021 | 21513 | 0.050 |
Why?
| | Biomarkers | 4 | 2013 | 4149 | 0.050 |
Why?
| | Blood Donors | 1 | 2004 | 105 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 658 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 405 | 0.050 |
Why?
| | Postmenopause | 1 | 2024 | 366 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2024 | 688 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 1066 | 0.050 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 55 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2003 | 318 | 0.050 |
Why?
| | Drainage | 1 | 2003 | 173 | 0.050 |
Why?
| | Vascular Diseases | 1 | 2005 | 243 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2016 | 4295 | 0.050 |
Why?
| | Partial Thromboplastin Time | 1 | 2021 | 57 | 0.050 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 210 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1250 | 0.040 |
Why?
| | Vascular Remodeling | 1 | 2023 | 193 | 0.040 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2020 | 5 | 0.040 |
Why?
| | Rivaroxaban | 1 | 2023 | 255 | 0.040 |
Why?
| | Catheters | 1 | 2021 | 73 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2003 | 491 | 0.040 |
Why?
| | Brachial Artery | 2 | 1999 | 205 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5472 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 114 | 0.040 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 67 | 0.040 |
Why?
| | Proteomics | 2 | 2022 | 1111 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2002 | 234 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 318 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 396 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 145 | 0.040 |
Why?
| | Mass Screening | 1 | 2007 | 1287 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1738 | 0.040 |
Why?
| | Smoking | 1 | 2007 | 1627 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 218 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2607 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 1266 | 0.040 |
Why?
| | Enalapril | 1 | 1998 | 16 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 722 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2022 | 267 | 0.040 |
Why?
| | Antigens, Ly | 1 | 2017 | 44 | 0.030 |
Why?
| | Survival Rate | 1 | 2022 | 1972 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 364 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 104 | 0.030 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 2 | 2010 | 51 | 0.030 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 201 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2021 | 706 | 0.030 |
Why?
| | Education | 1 | 2017 | 108 | 0.030 |
Why?
| | Th2 Cells | 1 | 2017 | 176 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 806 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 5079 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 243 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2475 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 563 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 485 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2016 | 844 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 9 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 2199 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 810 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2691 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2189 | 0.020 |
Why?
| | Perioperative Period | 1 | 2012 | 56 | 0.020 |
Why?
| | Mice | 2 | 2007 | 17787 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2020 | 871 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2011 | 24 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 147 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2011 | 52 | 0.020 |
Why?
| | International Cooperation | 1 | 2012 | 198 | 0.020 |
Why?
| | Vascular Endothelial Growth Factors | 2 | 2002 | 79 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2011 | 118 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2011 | 239 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2018 | 7635 | 0.020 |
Why?
| | Nitric Oxide | 2 | 2010 | 915 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2837 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2011 | 167 | 0.020 |
Why?
| | Introns | 1 | 2011 | 258 | 0.020 |
Why?
| | Physical Examination | 1 | 2012 | 241 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2011 | 179 | 0.020 |
Why?
| | RNA Splicing | 1 | 2011 | 269 | 0.020 |
Why?
| | Leg | 1 | 2011 | 236 | 0.020 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 261 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2013 | 313 | 0.020 |
Why?
| | Anesthesia | 1 | 2012 | 189 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2833 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2002 | 545 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 36 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 54 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 660 | 0.020 |
Why?
| | Contrast Media | 1 | 2011 | 467 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1303 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2009 | 171 | 0.020 |
Why?
| | Endothelin-1 | 1 | 2010 | 182 | 0.020 |
Why?
| | Mutation | 3 | 2005 | 3958 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5757 | 0.020 |
Why?
| | Research | 1 | 2009 | 451 | 0.020 |
Why?
| | Protein Binding | 1 | 2011 | 2224 | 0.010 |
Why?
| | Young Adult | 1 | 2021 | 13209 | 0.010 |
Why?
| | Gene Expression | 1 | 2010 | 1502 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 363 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 324 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1502 | 0.010 |
Why?
| | Genes, Viral | 1 | 2003 | 88 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1710 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1719 | 0.010 |
Why?
| | Cyclins | 1 | 2003 | 91 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2757 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 108 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2167 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2005 | 406 | 0.010 |
Why?
| | DNA, Viral | 1 | 2003 | 364 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1998 | 3715 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 342 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 2001 | 168 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2654 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2003 | 812 | 0.010 |
Why?
| | Vasoconstriction | 1 | 2001 | 202 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2001 | 404 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 5778 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 565 | 0.010 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 1999 | 7 | 0.010 |
Why?
| | Administration, Sublingual | 1 | 1999 | 12 | 0.010 |
Why?
| | Nitroglycerin | 1 | 1999 | 17 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 6763 | 0.010 |
Why?
| | Lipoprotein(a) | 1 | 1999 | 67 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1999 | 203 | 0.010 |
Why?
| | Video Recording | 1 | 1999 | 180 | 0.010 |
Why?
| | Fibrinogen | 1 | 1999 | 168 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 1998 | 88 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 413 | 0.010 |
Why?
| | Reference Values | 1 | 1999 | 816 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 1998 | 259 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 1024 | 0.010 |
Why?
| | Military Personnel | 1 | 1999 | 544 | 0.010 |
Why?
|
|
Bull's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|